Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bristol-Myers Squibb (NY: BMY )

58.74 -0.04 (-0.07%)
Official Closing Price Updated: 7:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
66 67 Next >
Bristol Myers' Investigational Lung Cancer Candidate Shows High Response Rates
Bristol Myers Squibb & Co (NYSE: BMY) announced updated results from a TRIDENT-1 study, demonstrating that repotrectinib — a next-generation ROS1/TRK tyrosine kinase inhibitor (TKI) — continued to show... 
Via Benzinga
Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
2 Dividend Stocks to Buy Hand Over Fist
Both of these companies offer more than consistent income. 
Via The Motley Fool
(BMY) - Analyzing Bristol-Myers Squibb's Short Interest
Via Benzinga
2 Blue Chip Dividend Stocks That Are Top Buys in August
These two dividend-paying healthcare stocks stand out as top buys right now. 
Via The Motley Fool
Bristol Myers Squibb (BMY) Q2 2023 Earnings Call Transcript
BMY earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Bristol Myers Squibb Misses Q2 Earnings And Revenue Estimates
Bristol Myers Squibb came out with quarterly earnings of $1.75 per share. 
Via Talk Markets
UnitedHealth Group, Pioneer Natural Resources And A Credit Card Giant: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Karen Firestone of Aureus Asset Management named American Express Company (NYSE: BMY) as her 
Via Benzinga
Topics Credit Cards
Exposures Interest Rates
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies... 
Via Talk Markets
Pharma ETFs in Focus Post Q2 Earnings
Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth. 
Via Talk Markets
Topics ETFs
3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Robust pipelines make these three pharmaceutical stocks solid choices for investors looking for stocks to buy and hold for long-term gains 
Via MarketBeat
Exposures COVID-19
2 Dirt Cheap Dividend Stocks to Buy Right Now
Business never sleeps for these companies. 
Via The Motley Fool
Bristol-Myers Squibb, Toast And A Major REIT Stock: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners named Bristol-Myers Squibb Company (NYSE: BMY), which announced $4 billion aggregate accelerated 
Via Benzinga
Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Enters Into $4 Billion Aggregate Accelerated Share Repurchase Agreements
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
Should Dividend Investors Buy Bristol Myers Stock?
The drugmaker's near future may be bumpy, but it has a brighter future on the horizon. 
Via The Motley Fool
Looking for a Bargain? 7 Blue-Chip Stocks to Buy That Are Down 5% in 2023
These discounted blue-chip stocks boast robust underlying businesses which present amazing long-term upside potential ahead 
Via InvestorPlace
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Attractive Large Caps on Sale After Q2 Earnings
For investors that like to sift through the underperformers for good values, good factors to identify are market overreaction and healthy long-term outlooks. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes
Here are three millionaire maker drug stocks from companies whose drugs could make truly staggering profits. 
Via InvestorPlace
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 59 companies set new 52-week lows. 
Via Benzinga
Roku To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Friday
JP Morgan boosted the price target for Intel Corporation (NASDAQ: INTC) from $30 to $35. JP Morgan analyst Harlan Sur maintained an Underweight rating. Intel shares rose 6.8% to $36.91 in pre-market... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday, 56 stocks hit new 52-week lows. 
Via Benzinga
Bristol Myers Squibb's Stocks Falls on Q2 Miss, FY23 Forecast Cut As Two Of Its Top Drugs Face Generic Competition
Bristol Myers Squibb & Co (NYSE: BMY) said that its Q2 revenues of $11.23 billion declined 6% Y/Y, or 5% when adjusted for foreign exchange, due to lower sales of Revlimid, partially offset by in-line... 
Via Benzinga
US Stocks Buckle Up For Solid Open On Meta's Earnings Boost, Fed Relief — But Analyst Advises Some 'Value-Style' Rebalancing
Stocks could be heading to a higher open on Thursday, as traders digest some positive earnings reports and look ahead to another batch of economic data. 
Via Benzinga
Exscientia is the Sniper of the AI Drug Discovery Industry
News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.